

Review

Regulation of IP₃ receptors by cyclic AMP

Colin W. Taylor

Department of Pharmacology, University of Cambridge, Tennis Court Road, Cambridge CB2 1PD, UK

ARTICLE INFO

Article history:

Received 6 October 2016

Received in revised form 27 October 2016

Accepted 27 October 2016

Available online 6 November 2016

Keywords:

Ca²⁺ stores

Cyclic AMP

IP₃ receptor

Protein kinase A

Parathyroid hormone

Signalling junctions

ABSTRACT

Ca²⁺ and cAMP are ubiquitous intracellular messengers and interactions between them are commonplace. Here the effects of cAMP on inositol 1,4,5-trisphosphate receptors (IP₃Rs) are briefly reviewed. All three subtypes of IP₃R are phosphorylated by cAMP-dependent protein kinase (PKA). This potentiates IP₃-evoked Ca²⁺ release through IP₃R1 and IP₃R2, but probably has little effect on IP₃R3. In addition, cAMP can directly sensitize all three IP₃R subtypes to IP₃. The high concentrations of cAMP required for this PKA-independent modulation of IP₃Rs is delivered to them within signalling junctions that include type 6 adenylyl cyclase and IP₃R2.

© 2016 The Author. Published by Elsevier Ltd. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

Contents

1. Introduction.....	48
2. Regulation of IP ₃ Rs by PKA.....	49
3. Direct regulation of IP ₃ Rs by cAMP.....	49
4. Signalling to IP ₃ Rs at cAMP junctions.....	50
Acknowledgements.....	51
References.....	51

1. Introduction

Cyclic AMP and Ca²⁺ are ubiquitous intracellular messengers used by all eukaryotic cells from plants and animals to coordinate their behaviours in response to both extracellular signals and intracellular activity [1–3]. These messengers create a signalling ‘bottleneck’ through which many extracellular signals funnel to regulate diverse cellular responses. The capacity of a rather limited repertoire of intracellular messengers to selectively regulate cellular activities depends in large part on the spatial organization of the messengers within the cell, the time frames over which they are delivered, and interactions between messengers. The latter often

endows signalling pathways with capacities to function as coincidence detectors: conveying signals onward only when several conditions are met [4]. As might be expected of the prototypical intracellular messengers, analyses of the interactions between cAMP and Ca²⁺ have a long history [5,6] that has revealed interactions at many levels. Ca²⁺, for example, regulates formation and degradation of cAMP [2,7], and cAMP can regulate both the channels that allow Ca²⁺ to flow into the cytosol and the Ca²⁺ pumps that extrude it [8,9].

A ubiquitous pathway from extracellular stimuli to cytosolic Ca²⁺ signals is provided by receptors that stimulate phospholipase C (PLC), production of inositol 1,4,5-trisphosphate (IP₃) and thereby Ca²⁺ release through IP₃ receptors (IP₃R) [10]. Cyclic AMP also modulates this pathway by, for example, regulating PLC [11] and the coupling of receptors to PLC [12]. However, in this short review, I focus on just one level of interaction, that between cAMP and IP₃Rs [13,14]. IP₃R subunits are encoded by three genes in vertebrates. The three large, closely related subunits assemble into homo- and hetero-tetrameric structures, which form large-conductance Ca²⁺-permeable channels within

Abbreviations: AC, adenylyl cyclase; EPAC, exchange protein activated by cAMP; IP₃, inositol 1,4,5-trisphosphate; IP₃R, IP₃ receptor; IRAG, IP₃R-associated cGMP kinase substrate; IRBIT, IP₃R-binding protein released by IP₃; PKA, protein kinase A (cAMP-dependent protein kinase); PKG, protein kinase G (cGMP-dependent protein kinase); PLC, phospholipase C; P_o, single-channel open probability; PTH, parathyroid hormone.

E-mail address: cwt1000@cam.ac.uk

<http://dx.doi.org/10.1016/j.ceca.2016.10.005>

0143-4160/© 2016 The Author. Published by Elsevier Ltd. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

intracellular membranes, primarily those of the endoplasmic reticulum [10]. Opening of the central pore is initiated by binding of IP₃ to all four IP₃R subunits [15], which evokes conformational changes within the N-terminal domains of the IP₃R [16]. These conformational changes are proposed to facilitate binding of Ca²⁺, which then triggers opening of the pore. Hence, the IP₃R is itself a coincidence detector, responding only when provided with both cytosolic IP₃ and Ca²⁺. High-resolution structures of the N-terminal region of an IP₃R with and without IP₃ bound [16], and cryo-electron microscopy reconstructions of the entire IP₃R in a closed state [17] have begun to reveal the workings of the IP₃R machinery. However, the mechanisms linking IP₃ binding to channel gating are not yet fully resolved. While IP₃ and Ca²⁺ are the essential regulators of IP₃R gating, many additional signals modulate IP₃R behaviour [18]. My focus on cAMP therefore provides only a rather restricted view of the capacity of IP₃Rs to integrate information provided by different signalling pathways.

2. Regulation of IP₃Rs by PKA

Cyclic AMP-dependent protein kinase (protein kinase A, PKA), exchange cation channels (EPACs), cyclic nucleotide-activated cation channels (CNGs), and some cyclic nucleotide phosphodiesterases (PDEs) are the major targets of cAMP in mammals. At least some of these targets regulate IP₃-evoked Ca²⁺ signalling. PKA, for example, stimulates Ca²⁺ uptake into the sarcoplasmic reticulum, and EPACs through the small G protein rap2B stimulate PLC ϵ [11]. However, only PKA has been convincingly shown to interact directly with IP₃Rs. The three IP₃R subtypes are closely related, but each has a distinctive distribution of PKA phosphorylation sites. The many effects of cAMP within Ca²⁺ signalling pathways were sources of some confusion in the pioneering studies of IP₃R phosphorylation [19], but the consensus now is that PKA-mediated phosphorylation of IP₃R1 and IP₃R2 enhances their activity, while the functional significance of such phosphorylation for IP₃R3 is less clear [14,20].

Two residues (S¹⁵⁸⁹ and S¹⁷⁵⁵) within the central cytosolic domain of IP₃R1 are phosphorylated by PKA, and their replacement by non-phosphorylatable alanine residues confirms that they are the only sites [21]. Phosphorylation of IP₃R1 by PKA or introduction of phosphomimetic residues (S¹⁵⁸⁹E/S¹⁷⁵⁵E) do not themselves open the channel, but they increase the open probability (P_o) of channels activated by IP₃. The increased P_o results from shortening of the gaps between bursts of channel openings and an increase in the duration of the bursts, with no obvious effect on IP₃ binding or the sensitivity to Ca²⁺ regulation [22]. Hence, phosphorylation of IP₃R1 by PKA improves the coupling of IP₃ and Ca²⁺ binding to channel gating by both stabilizing the bursting state of the IP₃R and destabilizing a prolonged closed state. An alternative splice site (S2, residues 1693–1732), which encodes 40 residues and is removed from non-neuronal IP₃R1, abuts the second phosphorylation site (S¹⁷⁵⁵). For the neuronal S2⁺ form of IP₃R1, S¹⁷⁵⁵ entirely mediates the effects of PKA, while in the peripheral S2⁻ form both residues (S¹⁵⁸⁹ and S¹⁷⁵⁵) must be phosphorylated for PKA to enhance IP₃-evoked Ca²⁺ release [23]. Effective phosphorylation and dephosphorylation of IP₃R1 are facilitated by tethering of PKA to IP₃R1 by AKAP9 (A-kinase-anchoring protein 9) [24] and of the protein phosphatase, PP1 α , by IRBIT [25], AKAP9 or directly to the C-terminal tail of IP₃R1 [26].

The consensus sequences for PKA and cGMP-dependent protein kinase (PKG) are similar, such that some residues (e.g. S¹⁷⁵⁵ in IP₃R1S2⁺) are phosphorylated by either kinase. Yet in native tissues PKG and PKA often exert opposing effects on IP₃-evoked Ca²⁺ release. The difference may, at least in part, be due to expression of IRAG (IP₃R-associated cGMP kinase substrate), which

blocks phosphorylation of IP₃R1 by PKA, and IRAG phosphorylated by PKG inhibits IP₃R [27]. Hence, IRAG diverts PKG from the PKA-phosphorylation sites and imposes its own inhibition. PKA also modulates the interaction of IP₃R1 with its endogenous antagonist, IRBIT (IP₃R-binding protein released by IP₃), apparently decreasing the affinity for IRBIT so that IP₃ more effectively competes for occupancy of their shared binding site on the IP₃R [28]. Hence in secretory epithelia, receptors that stimulate formation of cAMP and IP₃ synergistically stimulate release of IRBIT from IP₃Rs, and IRBIT then directly stimulates two of the ion transporters that sustain fluid transport [28].

Long before the discovery IP₃Rs, synergistic stimulation of a Ca²⁺-sensitive K⁺ channel by α_1 -adrenoceptors (which stimulate PLC) and β -adrenoceptors (which stimulate formation of cAMP) in hepatocytes suggested that cAMP might enhance receptor-mediated Ca²⁺ release from intracellular stores [29]. Subsequent studies confirmed that PKA stimulates phosphorylation of hepatic IP₃Rs [30] and potentiates IP₃-evoked Ca²⁺ release [31,32]. IP₃R2, the major IP₃R subtype in hepatocytes, is phosphorylated by PKA at a single residue (Ser⁹³⁷), although others suggest that IP₃R2 is a rather poor substrate for PKA [20]. Ser⁹³⁷ is unique to IP₃R2, but the functional consequences of the phosphorylation appear similar to those seen with IP₃R1, namely enhanced bursts of IP₃R gating [33]. Additional effects of PKA, including an increase in IP₃ binding affinity [30] and recruitment of IP₃Rs into functional Ca²⁺ stores [32], may also contribute to the effects of PKA on IP₃R2 in intact cells.

The effects of PKA on IP₃R3 have been least explored. In intact cells, IP₃R3 is phosphorylated by PKA at three sites (S⁹¹⁶, S⁹³⁴, S¹⁸³²) that are unique to IP₃R3, with S⁹³⁴ being the most extensively phosphorylated [34]. But, at least in cells expressing only IP₃R3, PKA has no effect on IP₃-evoked Ca²⁺ release triggered by cell-surface receptors [34]. Whether the phosphorylation affects other aspects of IP₃R3 behaviour remain to be determined.

3. Direct regulation of IP₃Rs by cAMP

In HEK-293 cells stably expressing human type 1 receptors for parathyroid hormone (PTH), PTH stimulates formation of cAMP, but it does not alone evoke an increase in cytosolic Ca²⁺ concentration ([Ca²⁺]_c). However, PTH potentiates the increase in [Ca²⁺]_c evoked by receptors that stimulate PLC, the endogenous muscarinic M₃ receptors of HEK-293 cells, for example, which can be activated by carbachol (Fig. 1A). This effect of PTH is mimicked by stimulation of endogenous prostanoid receptors or β -adrenoceptors, by direct activation of adenylyl cyclase with forskolin or by addition of a membrane-permeant analog of cAMP, 8-Br-cAMP. The non-additive effects of maximally effective concentrations of PTH and 8-Br-cAMP confirm that the effect of PTH on carbachol-evoked Ca²⁺ signals is entirely mediated by cAMP (Fig. 1B) [35,36]. Responses to other PLC-coupled receptors are also potentiated by PTH, and the enhanced responses are not associated with increased production of IP₃ [35,37]. Furthermore, cAMP also potentiates the Ca²⁺ signals evoked by a membrane-permeant form of IP₃ (IP₃-BM) [38]. These results, demonstrating that cAMP acts downstream of IP₃, are important because cAMP can, through EPACs, stimulate PLC ϵ [11]. However, the effects of PTH are neither mimicked by EPAC-selective analogs of cAMP [36] nor blocked by an EPAC antagonist [39]. The enhanced IP₃-evoked increases in [Ca²⁺]_c are not due to inhibition of Ca²⁺ extrusion from the cytosol by cAMP [38]. Furthermore, cAMP potentiates IP₃-evoked Ca²⁺ release in permeabilized cells [40], and it enhances IP₃-gated channel activity in nuclear patch-clamp recordings of IP₃R [40]. These results, where cAMP potentiates the activation of IP₃R by IP₃, seem consistent with the many reports suggesting that phosphorylation of IP₃R1 and IP₃R2 by PKA enhances responses to IP₃ (see preceding section). However,




Fig. 1. Regulation of IP₃Rs by cAMP signalling junctions.

(A) Populations of fluo4-loaded HEK-293 cells stably expressing type 1 receptors for PTH were stimulated with PTH (100 nM, red line) and carbachol (20 μM, both lines) as indicated after addition of BAPTA to chelate extracellular Ca²⁺. Results show that PTH does not alone evoke an increase in [Ca²⁺]_i, but it potentiates the Ca²⁺ signal evoked by carbachol. Similar results are shown in Refs. [36,39]. (B) In HEK-293 cells, PTH through heterologously expressed type 1 PTH receptors stimulates adenylyl cyclase and so formation of cAMP. Carbachol stimulates endogenous M₃ muscarinic receptors, which activate PLC and thereby formation of IP₃ and release of Ca²⁺ from the ER through IP₃Rs. The potentiation of carbachol-evoked Ca²⁺ signals by PTH is entirely mediated by cAMP, which enhances IP₃-evoked Ca²⁺ release from IP₃Rs. (C) IP₃R2 and AC6 are selectively associated at cAMP signalling junctions. Within these junctions, cAMP is delivered from AC to IP₃Rs at concentrations far greater than needed to maximally sensitize the associated IP₃Rs. This allows each junction to function as a digital 'on-off' switch, it ensures that cAMP-mediated signalling operates with a considerable safety margin, and it allows rapid activation of the associated IP₃Rs (as cAMP is locally delivered at high concentration) and rapid deactivation (as diffusion of cAMP from the junction reduces its concentration to below that needed for sensitizing IP₃Rs). Since each signalling junction operates as an 'on-off' switch, the concentration-dependent effects of PTH are proposed to be due to recruitment of junctions, rather than to graded activity within individual junctions.

several lines of evidence demonstrate that this is not a sufficient explanation:

1. When PTH-evoked protein phosphorylation is blocked by inhibition of either PKA activity (using H89) or the association of PKA with A-kinase-anchoring proteins (AKAPs, using a membrane-permeant form of an uncoupling protein, ht-89), there is no effect on the ability of any concentration of PTH to potentiate the Ca²⁺ signals evoked by carbachol [36,38,39]. Others have also suggested that potentiation of carbachol-evoked Ca²⁺ signals by β₂-adrenoceptors is insensitive to inhibition of PKA in HEK-293 cells [41]. Similar results were reported for rat osteoblasts, where potentiation of ATP-evoked Ca²⁺ signals by PTH was unaffected by inhibition of PKA [42].
2. In permeabilized HEK-293 cells, the catalytic subunit of PKA causes minimal phosphorylation of IP₃R and a barely detectable increase in the sensitivity of the Ca²⁺ stores to IP₃, while cAMP and 8-Br-cAMP cause substantial increases in IP₃ sensitivity [36].

3. The concentrations of 8-Br-cAMP (in intact cells) and of cAMP (in permeabilized cells) needed to sensitize IP₃Rs to IP₃ are much higher than those required to activate PKA [36].
4. In DT40 cells expressing single IP₃R subtypes, high concentrations of cAMP potentiate IP₃-evoked Ca²⁺ release through IP₃R1, IP₃R2 and IP₃R3 [40]. This does not align with the consensus that PKA increases the sensitivity of only IP₃R1 and IP₃R2 [14].
5. In permeabilized DT40 cells expressing IP₃R2, cAMP potentiates the Ca²⁺ release evoked by IP₃, and the effect of cAMP is unaffected by addition of either H89 (to inhibit PKA) or the catalytic subunit of PKA.
6. In nuclear patch-clamp recordings from IP₃R2 expressed in DT40 cells and stimulated with IP₃, cAMP increases channel activity in the absence of ATP [40], confirming that protein phosphorylation is not required.

These observations suggest that cAMP can regulate IP₃R activity via both PKA and by mechanisms that do not require activation of either PKA or EPACs. The observations are intriguing because they suggest an effect of cAMP that is not mediated by any of its conventional targets. Our results indicate that while cAMP alone cannot activate IP₃Rs and nor does cAMP affect IP₃ binding to IP₃Rs [40], it does enhance the effectiveness with which the essential co-agonists, IP₃ and Ca²⁺, stimulate channel opening. The mechanisms underlying these non-canonical actions of cAMP are not yet resolved. In light of evidence that the effects of cAMP are preserved in isolated nuclei and permeabilized cells [36,40], it seems likely that binding of cAMP to a low-affinity site within either the IP₃R itself or a tightly associated protein mediates this allosteric regulation of IP₃Rs by cAMP.

4. Signalling to IP₃Rs at cAMP junctions

Despite compelling evidence that cAMP entirely mediates the potentiating effects of PTH on IP₃-evoked Ca²⁺ signals [36], there are some puzzling features of the signalling pathway that initially led us to a different conclusion. Firstly, the direct effects of cAMP on IP₃Rs require much higher concentrations of cAMP than are needed for activation of PKA or EPACs, and probably much higher than the average concentrations achieved in stimulated cells [36]. Secondly, although many different stimuli evoke cAMP formation and potentiation of carbachol-evoked Ca²⁺ signals, the relationship between their effects on cAMP and Ca²⁺ are entirely different for different stimuli. For example, for concentrations of PTH and isoproterenol (which activates β-adrenoceptors) that cause similar submaximal potentiation of Ca²⁺ signals, PTH evokes a more than 10-fold greater increase in intracellular cAMP concentration than does isoproterenol [36]. This immediately suggests that the cAMP that regulates IP₃R activity cannot be uniformly distributed in the cytosol. Thirdly, and more troublesome, are the many manipulations of cAMP formation that fail to affect the carbachol-evoked Ca²⁺ signals. Hence substantial inhibition of cAMP formation by either low-affinity inhibitors of adenylyl cyclase (AC, ~90% inhibition in Ref. [38] and ~70% in Ref. [36]) or siRNA-mediated knockdown of AC3 (the major subtype in HEK-293 cells), or an enhancement of cAMP accumulation after inhibition of cyclic nucleotide phosphodiesterase [36,38,39] had no effect on the ability of any concentration of PTH to potentiate carbachol-evoked Ca²⁺ signals. This initially led us to conclude that the effects of PTH were not mediated by cAMP [38], but we had then to revise that conclusion in light of evidence that cAMP *does* mediate the effects of PTH.

It is easy to envisage how the effects of a maximal concentration of PTH might be unaffected by even very substantial inhibition of AC if there are 'spare receptors', such that maximal activation of the receptors can provide more cAMP than needed to cause

maximal activation of IP₃Rs. However, that argument cannot be employed to explain the lack of effect of AC inhibitors on the Ca²⁺ responses evoked by *submaximal* concentrations of PTH. We therefore proposed that the ‘spare’ signalling capacity might exist within subcellular compartments or ‘signalling junctions’. We suggest that cAMP is delivered to IP₃Rs locally at concentrations substantially greater than required to cause maximal sensitization of the associated IP₃Rs (Fig. 1C). The concentration-dependent effects of PTH, we suggest, come from recruitment of these hyperactive signalling junctions, rather than from graded activity within individual junctions. Each signalling junction is, in effect, an ‘on-off’ switch with a considerable safety margin because once activated it delivers more cAMP than needed to fully sensitize the associated IP₃Rs. Our scheme neatly accounts for both the inconsistent relationship between cAMP and response for different stimuli (because different stimuli operate with different safety margins) and it provides a mechanism that would allow IP₃Rs to be exposed to high concentrations of cAMP. It also accommodates the results showing that even manipulations of cAMP concentration fail to effect the Ca²⁺ signals evoked by PTH (because the large safety margin protects the signalling pathway from even substantial perturbations of cAMP).

The involvement of signalling junctions is supported by additional evidence [36]. Notably, there is a selective association between AC6 (which accounts for only 5% of AC in HEK-293 cells) and IP₃R2 in HEK-293 cells, consistent with targeted delivery of cAMP from AC to IP₃R. Loss of IP₃R2 (using siRNA) selectively attenuates the potentiation of carbachol-evoked Ca²⁺ signals by PTH. Global inhibition of AC activity by low-affinity inhibitors reduces PTH-evoked cAMP formation without affecting Ca²⁺ signals, whereas the converse occurs when expression of AC6 is reduced. Loss of AC6 has no perceptible effect on cAMP levels, but it attenuates the potentiation of carbachol-evoked Ca²⁺ signals by PTH. The rationale, we suggest, is that all signalling junctions feel the effect of the low-affinity inhibitors, which thereby reduces the cAMP delivered within junctions but not sufficiently to obliterate the safety margin, whereas removing AC6 from individual junctions (each perhaps containing only a single AC) will incapacitate that junction. Finally, in cells with diminished expression of α_s , which couples receptors to AC, the safety margin is reduced such that further inhibition of AC (using the low-affinity AC inhibitors) does reduce the ability of PTH to potentiate carbachol-evoked Ca²⁺ signals [36].

In conclusion, there are at least two routes through which cAMP can directly modulate IP₃R gating. Phosphorylation of IP₃R1 and IP₃R2 by PKA increases the effectiveness with which IP₃ and Ca²⁺ evoke bursts of channel openings. In addition, binding of cAMP to a low-affinity site that seems to be closely associated with the IP₃R can also increase the apparent efficacy of IP₃ and Ca²⁺ in gating each IP₃R subtype. The need for high concentrations of cAMP for this direct action demands local delivery of cAMP to IP₃Rs, and that has so far been shown to occur for only IP₃R2 [36]. The low-affinity of IP₃Rs for cAMP effectively insulates them from global changes in cytosolic cAMP concentration and allows them to respond only to cAMP delivered to them within signalling junctions (Fig. 1C). Because each active junction delivers cAMP at a super-saturating concentration to associated IP₃Rs, the junction behaves as a robust digital switch that can rapidly respond to changes in extracellular stimulus intensity. The cAMP is delivered rapidly and at a high concentration driving rapid association of cAMP with IP₃Rs, and as soon as the AC stimulus is removed the focal concentration of cAMP dissipates by diffusion, rapidly terminating the effects of cAMP on IP₃Rs.

Acknowledgements

Supported by the Wellcome Trust (101844) and Biotechnology and Biological Sciences Research Council UK (BB/L000075/1).

References

- [1] C. Gehring, Adenyl cyclases and cAMP in plant signaling—past and present, *Cell Commun. Signal.* 8 (2010) 15–19.
- [2] D.M. Cooper, V.G. Tabbasum, Adenylate cyclase-centred microdomains, *Biochem. J.* 462 (2014) 199–213.
- [3] M.J. Berridge, Unlocking the secrets of cell signaling, *Annu. Rev. Physiol.* 67 (2005) 1–21.
- [4] D. Bray, Protein molecules as computational elements in living cells, *Nature* 376 (1995) 307–312.
- [5] H. Rasmussen, Cell communication, calcium ion, and cyclic adenosine monophosphate, *Science* 170 (1970) 404–412.
- [6] M.J. Berridge, The interaction of cyclic nucleotides and calcium in the control of cellular activity, *Adv. Cyclic Nucl. Prot. Phos. Res.* 6 (1975) 1–98.
- [7] K. Omori, J. Kotera, Overview of PDEs and their regulation, *Circ. Res.* 100 (2007) 309–327.
- [8] I. Vandecaetsbeek, P. Vangheluwe, L. Raeymaekers, F. Wuytack, J. Vanoevelen, The Ca²⁺ pumps of the endoplasmic reticulum and Golgi apparatus, *Cold Spring Harb. Perspect. Biol.* (2012) a004184.
- [9] W.A. Catterall, Voltage-gated calcium channels, *Cold Spring Harb. Perspect. Biol.* 3 (2012) a003947.
- [10] C.W. Taylor, S.C. Tovey, IP₃ receptors: toward understanding their activation, *Cold Spring Harb. Perspect. Biol.* 2 (2012) a004010.
- [11] M. Schmidt, S. Evellin, P.A.O. Weernink, F. vom Dorp, H. Rehmann, J.W. Lomasney, et al., A new phospholipase-C-calcium signalling pathway mediated by cyclic AMP and a Rap GTPase, *Nat. Cell Biol.* 3 (2001) 1020–1024.
- [12] S.J. Morgan, D.A. Deshpande, B.C. Tiegs, A.M. Misor, H. Yan, A.V. Hershfeld, et al., β -Agonist-mediated relaxation of airway smooth muscle is protein kinase A-dependent, *J. Biol. Chem.* 289 (2014) 23065–23074.
- [13] V. Vanderheyden, B. Devogelaere, L. Missiaen, H. De Smedt, G. Bultynck, J.B. Parys, Regulation of inositol 1,4,5-trisphosphate-induced Ca²⁺ release by reversible phosphorylation and dephosphorylation, *Biochim. Biophys. Acta* 1793 (2009) 959–970.
- [14] M.J. Betzenhauser, D.I. Yule, Regulation of inositol 1,4,5-trisphosphate receptors by phosphorylation and adenine nucleotides, *Curr. Top. Membr.* 66 (2010) 273–298.
- [15] K.J. Alzayady, L. Wang, R. Chandrasekhar, L.E. Wagner 2nd, F. Van Petegem, D.I. Yule, Defining the stoichiometry of inositol 1,4,5-trisphosphate binding required to initiate Ca²⁺ release, *Sci. Signal.* 9 (2016) ra35.
- [16] M.-D. Seo, S. Velamakanni, N. Ishiyama, P.B. Stathopoulos, A.M. Rossi, S.A. Khan, et al., Structural and functional conservation of key domains in InsP₃ and ryanodine receptors, *Nature* 483 (2012) 108–112.
- [17] G. Fan, M.L. Baker, Z. Wang, M.R. Baker, P.A. Sinyagovskiy, W. Chiu, et al., Gating machinery of InsP₃R channels revealed by electron cryomicroscopy, *Nature* 527 (2015) 336–341.
- [18] D.L. Prole, C.W. Taylor, Inositol 1,4,5-trisphosphate receptors and their protein partners as signalling hubs, *J. Physiol.* 594 (2016) 2849–2866.
- [19] S. Supattapone, S.K. Danoff, A. Theibert, S.K. Joseph, J. Steiner, S.H. Snyder, Cyclic AMP-dependent phosphorylation of brain inositol trisphosphate receptor decreases its release of calcium, *Proc. Natl. Acad. Sci. U. S. A.* 85 (1988) 8747–8750.
- [20] M.D. Soulsby, R.J. Wojcikiewicz, Calcium mobilization via type III inositol 1,4,5-trisphosphate receptors is not altered by PKA-mediated phosphorylation of serines 916, 934, and 1832, *Cell Calcium* 42 (2007) 261–270.
- [21] M.D. Soulsby, K. Alzayady, Q. Xu, R.J. Wojcikiewicz, The contribution of serine residues 1588 and 1755 to phosphorylation of the type I inositol 1,4,5-trisphosphate receptor by PKA and PKG, *FEBS Lett.* 557 (2004) 181–184.
- [22] L.E. Wagner 2nd, S.K. Joseph, D.I. Yule, Regulation of single inositol 1,4,5-trisphosphate receptor channel activity by protein kinase A phosphorylation, *J. Physiol.* 586 (2008) 3577–3596.
- [23] L.E. Wagner, W.-H. Li, D.L. Yule, Phosphorylation of type 1 inositol 1,4,5-trisphosphate receptors by cyclic nucleotide-dependent protein kinases, *J. Biol. Chem.* 278 (2003) 45811–45817.
- [24] H. Tu, T.-S. Tang, Z. Wang, I. Bezprozvanny, Association of type 1 inositol 1,4,5-trisphosphate receptor with AKAP9 (Yotiao) and protein kinase A, *J. Biol. Chem.* 279 (2004) 19375–19382.
- [25] B. Devogelaere, M. Beullens, E. Sammels, R. Derua, E. Waelkens, J. van Lint, et al., Protein phosphatase-1 is a novel regulator of the interaction between IRBIT and the inositol 1,4,5-trisphosphate receptor, *Biochem. J.* 407 (2007) 303–311.
- [26] T.-S. Tang, H. Tu, Z. Wang, I. Bezprozvanny, Modulation of type 1 inositol (1,4,5)-trisphosphate receptor function by protein kinase A and protein phosphatase 1a, *J. Neurosci.* 23 (2003) 403–415.
- [27] W. Masuda, M.J. Betzenhauser, D.I. Yule, InsP₃-associated cGMP kinase substrate determines inositol 1,4,5-trisphosphate receptor susceptibility to phosphoregulation by cyclic nucleotide-dependent kinases, *J. Biol. Chem.* 285 (2010) 37927–37938.

- [28] S. Park, N. Shcheynikov, J.H. Hong, C. Zheng, S.H. Suh, K. Kawaai, et al., Irbit mediates synergy between Ca^{2+} and cAMP signaling pathways during epithelial transport in mice, *Gastroenterology* 145 (2013) 232–241.
- [29] D.H. Jenkinson, K. Koller, Interactions between the effects of α - and β -adrenoceptor agonists and adenine nucleotides on the membrane potential of cells in guinea-pig liver slices, *Br. J. Pharmacol.* 59 (1977) 163–175.
- [30] S.K. Joseph, S.V. Ryan, Phosphorylation of the inositol trisphosphate receptor in isolated rat hepatocytes, *J. Biol. Chem.* 268 (1993) 23059–23065.
- [31] G.M. Burgess, G.S.J. Bird, J.F. Obie, J.W. Putney Jr., The mechanism for synergisms between phospholipase C- and adenylylcyclase-linked hormones in liver, *J. Biol. Chem.* 266 (1991) 4772–4781.
- [32] G. Hajnóczky, E. Gao, T. Nomura, J.B. Hoek, A.P. Thomas, Multiple mechanisms by which protein kinase A potentiates inositol 1,4,5-trisphosphate-induced Ca^{2+} release in permeabilized hepatocytes, *Biochem. J.* 293 (1993) 413–422.
- [33] M.J. Betzenhauser, J.L. Fike, L.E. Wagner 2nd, D.I. Yule, Protein kinase A increases type-2 inositol 1,4,5-trisphosphate receptor activity by phosphorylation of serine 937, *J. Biol. Chem.* 284 (2009) 25116–25125.
- [34] M.D. Soulsby, R.J. Wojcikiewicz, The type III inositol 1,4,5-trisphosphate receptor is phosphorylated by cAMP-dependent protein kinase at three sites, *Biochem. J.* 392 (2005) 493–497.
- [35] A.D. Short, C.W. Taylor, Parathyroid hormone controls the size of the intracellular Ca^{2+} stores available to receptors linked to inositol trisphosphate formation, *J. Biol. Chem.* 275 (2000) 1807–1813.
- [36] S.C. Tovey, S.G. Dedos, E.J.A. Taylor, J.E. Church, C.W. Taylor, Selective coupling of type 6 adenylyl cyclase with type 2 IP_3 receptors mediates a direct sensitization of IP_3 receptors by cAMP, *J. Cell Biol.* 183 (2008) 297–311.
- [37] S.C. Tovey, C.W. Taylor, Cyclic AMP directs inositol (1,4,5)-trisphosphate-evoked Ca^{2+} signalling to different intracellular Ca^{2+} stores, *J. Cell Sci.* 126 (2013) 2305–2313.
- [38] S.C. Tovey, T.A. Goraya, C.W. Taylor, Parathyroid hormone increases the sensitivity of inositol trisphosphate receptors by a mechanism that is independent of cyclic AMP, *Br. J. Pharmacol.* 138 (2003) 81–90.
- [39] A. Meena, S.C. Tovey, C.W. Taylor, Sustained signalling by PTH modulates IP_3 accumulation and IP_3 receptors via cyclic AMP junctions, *J. Cell Sci.* 128 (2015) 408–420.
- [40] S.C. Tovey, S.G. Dedos, T. Rahman, E.J.A. Taylor, E. Pantazaka, C.W. Taylor, Regulation of inositol 1,4,5-trisphosphate receptors by cAMP independent of cAMP-dependent protein kinase, *J. Biol. Chem.* 285 (2010) 12979–12989.
- [41] N. Kurian, C.J. Hall, G.F. Wilkinson, M. Sullivan, A.B. Tobin, G.B. Willars, Full and partial agonists of muscarinic M_3 receptors reveal single and oscillatory Ca^{2+} responses by β_2 -adrenoceptors, *J. Pharmacol. Exp. Ther.* 330 (2009) 502–512.
- [42] K.A. Buckley, S.C. Wagstaff, G. McKay, R.A. Hipskind, G. Bilbe, J.A. Gallagher, et al., Parathyroid hormone potentiates nucleotide-induced $[\text{Ca}^{2+}]_i$ release in rat osteoblasts independently of G_q activation or cyclic monophosphate accumulation, *J. Biol. Chem.* 276 (2001) 9565–9571.